Effects omega-3 fatty acid supplementation in the treatment of diabetes
Phase 3
- Conditions
- Diabetic Nephropathy.Glomerular disorders in diabetes mellitus (E10-E14 with common fourth character .2+)N08.3
- Registration Number
- IRCT201504095623N41
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Inclusion Criteria: Patients with diabetic nephropathy with FPG = 126 mg/dl less than 15 years of their disease aged 45 to 85 years.
Exclusion Criteria
The intake of omega-3 fatty acid supplements within the past 3 months
Uncontrolled diabetes mellitus
Current use of warfarin
Malignancy
Liver cirrhosis
Smoking
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tumor Necrosis Factor alpha (TNFa). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa.;Receptor of Tumor Necrosis Factor alpha (TNFa). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa.
- Secondary Outcome Measures
Name Time Method Receptor of Advanced Glycation End Products. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa.;Advanced Glycation End Products. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Fluorometeric method.